gms | German Medical Science

44. Kongress der Deutschen Gesellschaft für Rheumatologie, 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

31.08. - 03.09.2016, Frankfurt am Main

Poster Freitag, 02.09.2016
Posterwalk – Spondyloarthritiden V

Meeting Abstract (SP.25)

No Increase in Incidence of Inflammatory Bowel Disease Among Secukinumab-treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies

Schreiber S, Sands BE, Baeten D, Huang JQ, Gandhi K, Karyekar C, Fox T, Gaillez C
[Full Text]
Meeting Abstract (SP.26)

Comparison of Secukinumab and Adalimumab Monotherapy as First-line Biologic Therapy in Patients with Active Psoriatic Arthritis: Proposed Design of a Randomized, Double-blind, Active Control, Multicenter Study

Mpofu S, McInnes I, Ding K, Noseda E, Pricop L
[Full Text]
Meeting Abstract (SP.27)

Sustained improvement in skin symptoms, physical functioning, and qualitiy of life with secukinumab versus ustekinumab in patients with moderate-to-severe psoriasis and concomitant psoriatic arthritis: 52 week results from the CLEAR study

Thaci D, Gottlieb AB, Blauvelt A, Bhosekar V, Milutinovic M, Karyekar C
[Full Text]
Meeting Abstract (SP.28)

Therapie-refraktäre Monarthritis des Manubrium-Corpus sterni Gelenks

Braun M, Hartig I, Matveeva FI
[Full Text]
Meeting Abstract (SP.29)

Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placcebo-controlled trial, FUTURE 1

Rech J, Kavanaugh A, Hall S, Geusens P, Wang Z, Mpofu S
[Full Text]
Meeting Abstract (SP.30)

Patterns of early Endothelial Progenitor Cell regeneration in axial seronegative spondylarthritis

Patschan S, Vogt M, Bakhtiari D, Henze E, Müller GA, Patschan D
[Full Text]
Meeting Abstract (SP.31)

Secukinumab improves physical function and quality of life in patients with active ankylosing spondylitis: 2-year data from measure 1, a phase 3 randomised trial

Baraliakos X, Baeten D, Wei JCC, Geusens P, Talloczy Z, Gong Y, Porter B
[Full Text]
Meeting Abstract (SP.32)

Secukinumab shows significant efficacy in nail psoriasis: week 32 results from the TRANSFIGURE study

Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M
[Full Text]